Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 11/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.67 |
| ▸ | HPGD | P15428 | 8/20 | 0.67 |
| ▸ | GAA | P10253 | 7/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | FHIT | P49789 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22392262 | 0.99 | ADORA1 (1.00) | ADORA1MAPTALDH1A1HPGDGAA | |
| SCHEMBL2997287 | 0.92 | ADORA1 (0.85) | ADORA1MAPTALDH1A1HPGDGAA | |
| SCHEMBL2999543 | 0.90 | ADORA1 (0.82) | ADORA1MAPTALDH1A1HPGDGAA | |
| SCHEMBL351848 | 0.85 | ADORA1 (0.73) | ADORA1MAPTALDH1A1HPGDGAA | |
| Hydrochloric Acid SCHEMBL351847 | 0.83 | ADORA1 (0.74) | ADORA1MAPTALDH1A1HPGDGAA | |
| SCHEMBL1976488 | 0.80 | MAPT (0.94) | ADORA1MAPTALDH1A1HPGDGAA | |
| SCHEMBL133642 | 0.80 | MAPT (1.00) | ADORA1MAPTALDH1A1HPGDGAA | |
| SCHEMBL8203239 | 0.80 | MAPT (0.72) | ADORA1MAPTALDH1A1HPGDGAA | |
| SCHEMBL1887318 | 0.79 | ALDH1A1 (0.97) | ADORA1MAPTALDH1A1HPGDGAA | |
| SCHEMBL4090734 | 0.79 | ALDH1A1 (0.97) | ADORA1MAPTALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358972-B2 | Pentacyclic heterocycles | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| EP-3936190-A1 | PENTACYCLIC HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2022-01-12 | — | — | EP | disclosed |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| EP-0927184-B1 | 3-SUBSTITUTED PYRIDO 4',3':4,5]THIENO 2,3-D]PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE | ABBOTT GMBH & CO KG (DE) | 2003-10-22 | — | — | EP | disclosed |
| US-6387912-B1 | STROKE THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-6222034-B1 | AS SEROTININ RECEPTOR ANTAGONISTS; FOR THERAPY OF DEPRESSION, CENTRAL NERVOUS SYSTEM DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358972-B2 | Pentacyclic heterocycles | CYP2C19, CYP2C18, XDH | ADORA1 1600/4885MAPT 3678/4885ALDH1A1 352/4885 |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | CYP2C19, CYP2C18, XDH | ADORA1 1600/4885MAPT 3678/4885ALDH1A1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.